Ninth European International Kidney Cancer Symposium

25-26 April 2014
The Convention Centre Dublin
with the Gibson Hotel Dublin, Ireland

KidneyCancer.com

www.kidneycancersymposium.com
25 April 2014

11.15-12.45  Industry Sponsored Satellite Symposium and Lunch
13.00-13.10  Welcome
James Larkin, FRCP, Ph.D.
13.10-13.20  Kidney Cancer Association
Carolyn Konosky, MBA
Bernard Escudier, M.D.

Scientific Symposium
Chairs: James Larkin, FRCP, Ph.D., and Laurence Albiges, M.D.
13.45-14.15  Cancer Genes in RCC: Clinical Implications and Intratumour Heterogeneity: Is it Relevant in RCC?
Charles Swanton, FRCP, Ph.D.
14.15-14.45  T Cell Checkpoint Inhibitors in RCC: A New Hope?
David F. McDermott, M.D.
14.45-15.00  Audience Questions and Discussion
15.00-15.30  Break
15.30-16.30  Industry Sponsored Satellite Symposium
16.30-16.40  Break and Poster Session
16.40-17.30  Nurses’ Topics
Laura Wood, R.N., MSN, OCN
Lynda Pyle, R.N.

Treatment Options for Localized and Locally Advanced RCC
Chairs: Jean Jacques Patard, M.D., Ph.D.
Tim O’Brien, M.A., DM, FRCS
17.30-17.40  Debate: Robot-Assisted Partial Nephrectomy (RAPN) is the New Standard for Treatment of SRMs PRO
Christophe Vaessen, M.D.
17.40-17.50  Debate: Robot-Assisted Partial Nephrectomy (RAPN) is the New Standard for Treatment of SRMs CON
Börje Ljungberg, M.D., Ph.D.
17.50-18.00  Debate: Small Primary Hilar Endophytic Renal Tumours - Cryotherapy
Roberto Salvioni, M.D.
18.00-18.10  Debate: Small Primary Hilar Endophytic Renal Tumours - RFA
Miltiadis Krokidis, M.D., Ph.D., EBIR
18.10-18.20  Laparoscopic Radical Nephrectomy in Locally Advanced RCC: Anecdotal or the Future?
David Nicol, Ph.D., MBBS, FRACS
18.20-18.35  Surgical Strategy in RCC with IVC Invasion
Christopher G. Wood, M.D., FACS
18.35-19.00  Presentation of Cases/Audience Voting/Discussion/Panel
Jean Jacques Patard, M.D., Ph.D.
19.00  Adjourn
## 26 April 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.05</td>
<td>Welcome</td>
<td>Manuela Schmidinger, M.D.</td>
<td></td>
</tr>
<tr>
<td>08.05-08.20</td>
<td>Systemic mRCC Treatment</td>
<td>Camillo Porta, M.D.</td>
<td>John B. Haanen, M.D., Ph.D., Ron Bukowski, M.D.</td>
</tr>
<tr>
<td>08.20-08.35</td>
<td>Who is Your Ideal Sunitinib Patient?</td>
<td>Robert E. Hawkins, M.D., Ph.D., FRCP</td>
<td></td>
</tr>
<tr>
<td>08.35-08.50</td>
<td>Who is Your Ideal Pazopanib Patient?</td>
<td>Bernard Escudier, M.D.</td>
<td></td>
</tr>
<tr>
<td>08.50-09.05</td>
<td>Who is Your Ideal mTOR Inhibitor Patient?</td>
<td>Thomas E. Hutson, D.O., Pharm.D., FACP</td>
<td></td>
</tr>
<tr>
<td>09.05-09.20</td>
<td>What is the Hottest New Small Molecule in RCC?</td>
<td>Emiliano Calvo, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>09.20-09.35</td>
<td>Audience Questions and Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.35-09.50</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Open Questions in RCC

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.40-10.55</td>
<td>When No Treatment is the Best Treatment:</td>
<td>Brian I. Rini, M.D.</td>
<td>Lisa M. Pickering, MBBS, MA, MRCP, Ph.D., Viktor Grünwald, M.D.</td>
</tr>
<tr>
<td>10.55-11.10</td>
<td>Observation and Intermittent Strategies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.10-11.30</td>
<td>Negative Trials (RECORD2, 404, INTORACT, others) in RCC: Why We Went Wrong and Can We Do Better?</td>
<td>Tim Eisen, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>11.30-11.45</td>
<td>Tumor Microenvironment in RCC: Epithelial/Stromal Transition</td>
<td>Isaac P. Witz, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>11.45-11.55</td>
<td>Epithelial/Stromal Transition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.55-12.20</td>
<td>Audience Questions and Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.20-14.15</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Pathology and Prognosis

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.50-10.10</td>
<td>Prognostic Scoring Systems for RCC 2014:</td>
<td>Daniel Heng, M.D., M.P.H., FRCP</td>
<td>Lisa M. Pickering, MBBS, MA, MRCP, Ph.D., Viktor Grünwald, M.D.</td>
</tr>
<tr>
<td>10.05-10.20</td>
<td>How Does Histology Alter Treatment?</td>
<td>Cora N. Sternberg, M.D., FACP</td>
<td></td>
</tr>
<tr>
<td>10.20-10.40</td>
<td>Sarcomatoid Histology: What Should We Do?</td>
<td>Viktor Grünwald, M.D.</td>
<td></td>
</tr>
<tr>
<td>10.30-10.40</td>
<td>Epithelial/Stromal Transition</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**SCIENTIFIC PROGRAM**

Ninth European International Kidney Cancer Symposium
Dublin, Ireland — 25-26 April 2014
26 April 2014

Challenges From Treatment and From the Disease
Chairs: Manuela Schmidinger, M.D.
        Alan Ravaud, M.D., Ph.D.

14.15-14.30  Cardiac Toxicity and How to Get the Best
             Out of Potent Specific VEGFR TKIs
             Manuela Schmidinger, M.D.

14.30-14.45  Challenges for Patients on Long Term
             Systemic Therapy
             Cezary Szczylik, M.D.

14.45-15.00  Do We Need to Pay More Attention to Bone
             Metastases?
             Lisa M. Pickering, MBBS, MA, MRCP, Ph.D.

15.00-15.15  Does the Presence of Brain Metastases
             Influence Choice of Systemic Therapy?
             Sergio Bracarda, M.D.

15.15-15.30  Optimal Systemic Therapy in the Setting
             of Hepatic and Renal Dysfunction
             Thomas Powles, M.D., MBBS, MRCP

15.30-15.40  Audience Questions and Discussion

15.40        Adjourn